Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)

California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test

AUSTIN, Texas, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that California Medicaid (Medi-Cal) added Ova1Plus to its fee schedule. Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements beginning immediately and going back to date of service back to October 15, 2023.

The California Department of Health Care Services who is responsible for establishing policy and covered health care services for the California Medicaid (Medi-Cal) program, inclusive of both the fee-for-service and managed care delivery systems has added the Ova1Plus CPT 81503 to its Provider Manual and fee schedule at the Medicare rate of $897.

“We are pleased to announce Medi-Cal’s decision to add Ova1Plus to its fee schedule,” said Nicole Sandford, President and CEO of Aspira. “This means that women in California facing an ovarian cancer diagnosis, regardless of economic status, will have expanded access to this ground-breaking technology.”

About Aspira Women’s Health Inc. 
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite^SM, which includes OvaWatch, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus combines our FDA-cleared products, Ova1 and Overa, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.